Healthcare diagnostics startup Neuranics has successfully raised $700,000 in a seed funding round led by Inflection Point Ventures (IPV). The investment will fuel technology development and clinical validation, accelerating the company’s mission to transform blood diagnostics.
Neuranics is pioneering a point-of-care blood analyzer capable of delivering complete blood count (CBC) results in under 10 minutes using just a finger-prick sample. Designed for use in primary and emergency care settings, the device is low-maintenance and highly efficient, addressing a critical need in the healthcare sector.
The ability to obtain immediate, accurate CBC results at the point of care empowers physicians to make informed decisions on triage, further testing, and treatment while still with the patient. This eliminates delays caused by sample transport and preparation, benefiting patients through improved outcomes and physicians through enhanced diagnostic confidence. The technology also reduces healthcare costs, minimizes the misuse of medications like antibiotics, and ensures timely treatment for life-threatening conditions such as sepsis, severe anemia, and thrombocytopenia in dengue patients.
With its compact, dry hematology design, Neuranics is perfectly positioned to deliver critical blood diagnostics efficiently and effectively in resource-constrained environments.
Investor and Industry Insights
Mitesh Shah, Co-Founder of IPV, commented:
“Neuranics is addressing the challenge of lengthy and complex blood testing processes with a revolutionary point-of-care analyzer that makes CBC diagnostics faster and more accessible. This innovation significantly enhances patient care, particularly in urgent cases. IPV is confident in Neuranics’ vision and believes in its potential to deliver more such transformative solutions in the future.”
Dr. Megha Sharma, Chief Medical Evangelist at Neuranics, added:
“By using a simple finger-prick capillary sample, we’ve removed the need for traditional venipuncture, making blood testing faster, less invasive, and more patient-friendly. This technology empowers healthcare providers with immediate insights, especially in primary health centers and emergency setups, enabling better patient outcomes.”
A Leap Towards the Future
Neuranics has already secured a patent for its innovative technology, along with a CDSCO Test License, ethical approval from AIIMS Delhi, and is actively progressing through clinical trials.
Praveen Kumar, Co-Founder & CEO of Neuranics, emphasized:
“Our goal is to redefine diagnostics by bringing instant, accurate blood analysis closer to the patient without compromising quality. Leveraging AI on de-identified pathological imaging data generated by our analyzer, we aim to establish a new gold standard for national screening programs. This innovation will elevate India’s healthcare landscape and position the country as a global leader in point-of-care blood diagnostics.”
Market Potential
The global diagnostics industry, particularly the CBC market, is projected to reach $50 billion, growing at a CAGR of 8-10%. Neuranics’ expertise in precision robotics, machine vision, and microfluidics positions it as a frontrunner in next-generation diagnostic technologies, ready to revolutionize healthcare delivery worldwide.
